Table 1.

Baseline characteristics in International Prostate Symptom Score (IPSS) and uroflowmetry parameters, 3-day voiding diary (VD) of Groups A^a and B^b

Characteristic	Group A	Group B	P-value
Patients
N	209	196
Age, years	66.6±5.4	64.6±4.4	0.56
BMI, kg/m2	23.5±2.5	22.8±1.9	0.72
IPSS
Total	18.0±5.3	16.5±4.5	0.38
Voiding symptoms	9.0±3.2	8.4±3.5	0.64
Storage symptoms	9.0±2.7	8.1±2.5	0.73
Nocturia	2.9±0.5	2.8±1.1	0.86
OABSS	11.4±5.2	12.8±5.7	0.23
Uroflowmetry
Qmax, mL/second	13.5±4.7	14.9±5.9	0.17
PVR, mL	33.6±22.7	32.9±20.2	0.69
3-day VD
Nocturia episodes in 3 days, n	8.7±3.2	8.6±2.9	0.93
Nocturnal urine volume, mL	666.0±132.9	710.0±152.1	0.14
Nocturnal index	1.4±0.3	1.6±0.7	0.37
Urgency episodes in 3 days, n	5.6±2.9	5.9±1.9	0.54
NBC index	0.5±0.1	0.5±0.2	0.93

Notes: Values are mean ± standard deviation.

^aAlpha-blocker for 4 weeks, followed by alpha-blocker plus an anticholinergic agent for 4 weeks, then, lastly, an alpha-blocker plus an antidiuretic agent for 4 weeks

^balpha-blocker for 4 weeks, followed by alpha-blocker plus an antidiuretic agent for 4 weeks, then, lastly, an alpha-blocker plus an anticholinergic agent for 4 weeks.

Abbreviations: BMI, body-mass index; NBC, nocturnal bladder capacity; OABSS, Overactive Bladder Symptom Score; PVR, post-void residual urine; Q_max, maximum urinary flow rate; n, number.